Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients
- Conditions
- End Stage Renal DiseaseHeart Failure
- Registration Number
- NCT04061811
- Lead Sponsor
- Hannover Medical School
- Brief Summary
Objectives: The aim of this study is to determine whether growth differentiation factor-15 (GDF15) and circulating neprilysin (cNEP) improve the diagnosis of congestive heart failure (HF) in patients on dialysis.
Background: Dialysis patients are at increased risk of HF. However, diagnostic utility of NT-proBNP as a biomarker is decreased in patients on dialysis. GDF15 and cNEP are biomarkers of distinct mechanisms that may contribute to HF pathophysiology in such cohorts.
Methods: We compare circulating concentrations of NT-proBNP, GDF15, and cNEP along with NEP activity in patients on chronic dialysis without and with HF, as diagnosed by clinical parameters and post-dialysis echocardiography. We use correlation, linear and logistic regression as well as receiver operating characteristic (ROC) analyses.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 153
- ESRD on either chronic hemodialysis (HD) or peritoneal dialysis (PD) for ≥3 months
- previous switch of the type of renal replacement therapy from HD to PD or vice versa
- age <18 years
- pregnancy
- plasma exchange or apheresis in the past 6 months
- unipolar pacemaker
- history of whole extremity amputation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HF diagnosis Baseline (at study entry (diagnostic biomarker study)) Diagnosis of HF
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Inserm Umr S-942
🇫🇷Paris, France
Hannover Medical School
🇩🇪Hannover, Germany
Inserm Umr S-942🇫🇷Paris, France